Gene therapy for dopamine replacement
Brain Repair and Imaging in Neural Systems, Department of Experimental Medical Science, Lund University, Lund, Sweden. Progress in brain research
(Impact Factor: 2.83).
01/2010; 184:221-35. DOI: 10.1016/S0079-6123(10)84012-9
Dopamine replacement for Parkinson's disease (PD) have seen three major iterations of improvements since the introduction of l-3,4-dihydroxyphenylalanine (l-DOPA) pharmacotherapy: dopamine receptor agonists, ex vivo gene transfer for cell transplantation and most recently in vivo gene therapy. In this chapter, we describe the principles behind viral vector-mediated enzyme replacement in PD. We focus on the enzymes involved in the dopamine synthesis and their internal regulation, the early experimental work on gene therapy using different viral vector types and selection of transgenes, and finally discuss the recently completed early phase clinical trials in PD patients.
Available from: Afsaneh Gaillard
- "Apart from acting on the expression of guidance cues localized in the environment of the pathway, another way to improve the transplantation efficacy could be to modulate the expression of single or combined guidance cue receptors in the cells to be transplanted. Enhancing or repressing their response to environmental cues may be achieved using gene therapy, as it has been previously done to replace enzymes involved in the dopamine metabolism (for review, see Bjorklund et al., 2010). However, modifying the expression of guidance molecule receptors before transplantation would induce a modification of the axon guidance all along the nigrostriatal pathway, from the initial site of transplantation to the target site. "
[Show abstract] [Hide abstract]
ABSTRACT: Mesotelencephalic pathways in the adult central nervous system have been studied in great detail because of their implication in major physiological functions as well as in psychiatric, neurological, and neurodegenerative diseases. However, the ontogeny of these pathways and the molecular mechanisms that guide dopaminergic axons during embryogenesis have been only recently studied. This line of research is of crucial interest for the repair of lesioned circuits in adulthood following neurodegenerative diseases or common traumatic injuries. For instance, in the adult, the anatomic and functional repair of the nigrostriatal pathway following dopaminergic embryonic neuron transplantation suggests that specific guidance cues exist which govern embryonic fibers outgrowth, and suggests that axons from transplanted embryonic cells are able to respond to theses cues, which then guide them to their final targets. In this review, we first synthesize the work that has been performed in the last few years on developing mesotelencephalic pathways, and summarize the current knowledge on the identity of cellular and molecular signals thought to be involved in establishing mesotelencephalic dopaminergic neuronal connectivity during embryogenesis in the central nervous system of rodents. Then, we review the modulation of expression of these molecular signals in the lesioned adult brain and discuss their potential role in remodeling the mesotelencephalic dopaminergic circuitry, with a particular focus on Parkinson's disease (PD). Identifying guidance molecules involved in the connection of grafted cells may be useful for cellular therapy in Parkinsonian patients, as these molecules may help direct axons from grafted cells along the long distance they have to travel from the substantia nigra to the striatum.
Frontiers in Cellular Neuroscience 07/2012; 6:32. DOI:10.3389/fncel.2012.00032 · 4.29 Impact Factor
Available from: Yoland Smith
[Show abstract] [Hide abstract]
ABSTRACT: The demonstration that dopamine loss is the key pathological feature of Parkinson's disease (PD), and the subsequent introduction of levodopa have revolutionalized the field of PD therapeutics. This review will discuss the significant progress that has been made in the development of new pharmacological and surgical tools to treat PD motor symptoms since this major breakthrough in the 1960s. However, we will also highlight some of the challenges the field of PD therapeutics has been struggling with during the past decades. The lack of neuroprotective therapies and the limited treatment strategies for the nonmotor symptoms of the disease (ie, cognitive impairments, autonomic dysfunctions, psychiatric disorders, etc.) are among the most pressing issues to be addressed in the years to come. It appears that the combination of early PD nonmotor symptoms with imaging of the nigrostriatal dopaminergic system offers a promising path toward the identification of PD biomarkers, which, once characterized, will set the stage for efficient use of neuroprotective agents that could slow down and alter the course of the disease.
Neuropsychopharmacology: official publication of the American College of Neuropsychopharmacology 09/2011; 37(1):213-46. DOI:10.1038/npp.2011.212 · 7.05 Impact Factor
Available from: Moses P. Adoga
Edited by Moses P. Adoga, 01/2012; Intech Publishers, Croatia, Europe.., ISBN: 978-953-51-0369-1
Data provided are for informational purposes only. Although carefully collected, accuracy cannot be guaranteed. The impact factor represents a rough estimation of the journal's impact factor and does not reflect the actual current impact factor. Publisher conditions are provided by RoMEO. Differing provisions from the publisher's actual policy or licence agreement may be applicable.